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ABSTR ACT: Hepatocellular carcinoma (HCC), one of the leading causes of cancer deaths in the world, is offering a challenge to human beings, with the 
current modes of treatment being a palliative approach. Lack of proper curative or preventive treatment methods encouraged extensive research around the 
world with an aim to detect a vaccine or therapeutic target biomolecule that could lead to development of a drug or vaccine against HCC. Biomarkers or 
biological disease markers have emerged as a potential tool as drug/vaccine targets, as they can accurately diagnose, predict, and even prevent the diseases. 
Biomarker expression in tissue, serum, plasma, or urine can detect tumor in very early stages of its development and monitor the cancer progression and 
also the effect of therapeutic interventions. Biomarker discoveries are driven by advanced techniques, such as proteomics, transcriptomics, whole genome 
sequencing, micro- and micro-RNA arrays, and translational clinics. In this review, an overview of the potential of tissue- and serum-associated HCC bio-
markers as diagnostic, prognostic, and therapeutic targets for drug development is presented. In addition, we highlight recently developed micro-RNA, long 
noncoding RNA biomarkers, and single-nucleotide changes, which may be used independently or as complementary biomarkers. These active investigations 
going on around the world aimed at conquering HCC might show a bright light in the near future.
KEY WORDS: biomarker, HCC, liver, miRNA, lncRNA, prognosis, prevention, therapeutic
SUPPLEMENT: Biomarkers and their essential role in the Development 
of Personalised Therapies
CITATION: Chauhan and Lahiri. Tissue- and serum-associated Biomarkers  
of Hepatocellular Carcinoma. Biomarkers in Cancer 2016:8(s1) 37–55  
doi:10.4137/BiC.s34413.
TYPE: review
RECEIVED: January 17, 2016. RESUBMITTED: march 15, 2016. ACCEPTED FOR 
PUBLICATION: march 27, 2016.
ACADEMIC EDITOR: Barbara Guinn, editor in Chief
PEER REVIEW: Four peer reviewers contributed to the peer review report. reviewers’ 
reports totaled 354 words, excluding any confidential comments to the academic editor.
FUNDING: rC thanks Canadian institute of Health research for providing funds for 
postdoctoral fellowship. The authors confirm that the funder had no influence over the 
study design, content of the article, or selection of this journal.
COMPETING INTERESTS: NL is a scientist at Pfizer. RC worked as a postdoctoral 
research fellow in a Canadian institute of Health research-funded project (moP-14818) 
during inception and part of writing of this review. rC and nL have no roles in the 
discovery of any of the biomarker/s described in this review. Description of biomarkers 
given in this review is based on the recent developments in the field. The views are 
of authors, and there is no association or influence of any public or private company, 
institute, or person.
COPYRIGHT: © the authors, publisher and licensee Libertas academica Limited.  
This is an open-access article distributed under the terms of the Creative Commons  
CC-BY-nC 3.0 License.
CORRESPONDENCE: drchauhanr@gmail.com 
Paper subject to independent expert single-blind peer review. all editorial decisions 
made by independent academic editor. Upon submission manuscript was subject to 
anti-plagiarism scanning. Prior to publication all authors have given signed confirmation 
of agreement to article publication and compliance with all applicable ethical and legal 
requirements, including the accuracy of author and contributor information, disclosure of 
competing interests and funding sources, compliance with ethical requirements relating 
to human and animal study participants, and compliance with any copyright requirements 
of third parties. This journal is a member of the Committee on Publication ethics (CoPe).
Published by Libertas academica. Learn more about this journal.
Journal name: Biomarkers in Cancer
Journal type: Review
Year: 2016
Volume: 8(S1)
Running head verso: Chauhan and Lahiri
Running head recto: Tissue associated biomarkers of hepatocellular carcinoma
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common 
cancer worldwide and the third leading cause of cancer mor-
tality. HCC is defined as a primary tumorigenesis in the liver, 
mainly in patients suffering from chronic liver cirrhosis or 
hepatitis B or C. The tumor gradually spreads to hepatocytes and 
in advanced stages metastasizes to other organs, such as lungs 
and brain. HCC has become one of the very common cancers 
causing death, affecting more than 500,000 people in the world.1 
The other main risk factors for HCC are alcohol and aflatoxin.2,3
The Development of HCC
HCC is one of the major liver-related mortalities in cirrho-
sis. As shown in Figure 1, when the healthy liver is affected 
by hepatitis B virus (HBV) or hepatitis C virus (HCV), a 
gradual chronic infection leads to liver cirrhosis. Cirrhosis is 
characterized by a decrease in the growth of healthy hepato-
cytes and is due to degeneration and regeneration of cells.3 
Regeneration leads to increase in fibrous scar tissue following 
the destruction of the healthy liver cells, which provides the 
environment for forming cancerous tumors.4 Telomerase, 
which plays an important role in maintaining telomere length 
and chromosomal stability in hepatocytes5 and their shorten-
ing, limits the regenerative capacity of organs during chronic 
disease.6 In a cirrhotic liver, the telomeres of the hepatocytes 
are significantly shorter than in noncirrhotic tissue.6 Telomere 
dysfunctions, along with p53 mutation, are associated with 
the onset of early-stage hepatic neoplasms.7
Another characteristic of cirrhosis is the activation of 
stellate cells. This leads to an increase in the production of 
cytokines, growth factors, and products of oxidative stress, 
many of which have been shown to affect hepatocyte prolif-
eration and so could play a role in tumor formation.8
The main oncogenic pathways involved in HCC 
are phosphoinositol-3-kinase (PI3K)/Akt, myc, Wnt/β-
catenin, c-Met, and hedgehog (Fig. 1–4).9,10 Activation of 
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Akt signaling is thought to promote tumor formation by 
suppressing transforming growth factor (TGF)-β-induced 
apoptosis, which in turn activates Wnt/β-catenin signaling, 
so further driving the hepatocarcinogenic process.
Current HCC therapeutic and management 
methods. HCC patients are subjected to multiple treat-
ments, including transcatheter arterial chemoemboliza-
tion, brachytherapy with radioactive yytrium,11–13 and also 
cytokine/hormonal therapy, such as interleukin (IL)-2.14 A 
potent drug sorafenib, an oral agent with antiangiogenic, 
proapoptotic, and Raf-kinase inhibitory properties, has been 
safely evaluated in clinical phase II and phase III trials.15–17 
Several drugs modulating different cell signaling mecha-
nisms, mainly PI3K–Akt, mammalian target of rapamycin 
(mTOR), and RAF/MEK/ERK pathways, are being inves-
tigated for their effectiveness to control the progression 
of HCC. For example, KU-0060648 was found to inhibit 
HCC cell proliferation by both DNA-activated protein 
kinase-dependent and -independent me chanisms.18 A study 
involving VO-OHpic, a phosphatase and tensin homolog 
(PTEN) inhibitor in HCC cells, demonstrated that VO-
OHpic inhibited HCC cell viability, cell proliferation, and 
colony formation in synergy with PI3K/mTOR and RAF/
MEK/ERK pathway inhibitors.19 Antroquinonol, a tradi-
tional Chinese liver treatment drug, exhibited anticancer 
activity by activating 5′-adenosine mono phosphate (AMP) 
kinase and inhibiting mTOR pathway,20 leading to G1 cycle 
arrest and cellular apoptosis. In another study, it is shown 
that overexpression of far upstream element-binding pro-
tein in HCC and other cancers,21,22 which is directly regu-
lated by P13K/Akt/mTOR pathway, could be substantially 
reduced by sorafenib.23,24
Role of biomarkers in HCC. Biomarkers are the 
molecular indicators of the physiological status detect-
able in blood, urine, or tissue and can be important for the 
management of various diseases. Their concentrations and 
changes in body fluids can provide an estimate about the 
disease progression. Ideally, biomarkers should have high 
sensitivity of detection where there is small cancer, should 
be highly specific, and must not increase in noncancer. Their 
levels should increase with tumor progression and predict 
the prognosis. HCC is one such life-threatening condition 
that could be detected early or, in an optimistic note, hoped 
to be prevented by biomarkers’ therapeutic and prognostic 
capabilities. Table 1 lists various categories of biomarkers 
upregulated in HCC.
Tumor Tissue Biomarkers of HCC
The biopsies and extensive research on tumor tissues of HCC 
provide a wide range of information about the abnormal 
constituents of tumor cells and what constituent is upregu-
lated in transformed or neoplastic conditions. This informa-
tion has provided researchers with therapeutic targets for 
vaccine, drug development, and screening for surveillance 
Chronic inflammation
Healthy liver
Regeneration
Hepatocellular Carcinoma
HBV infection
HCV infection
Alcohol
Insult to liver
Aflatoxin
Metabolic disorders
Induction of very early biomarker/s
Not so healthy liver
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Induction of early biomarker/s
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Figure 1. stages of Hepatocellular carcinoma development and induction of biomarkers. Highlighted liver indicates decisive stage during which liver is 
either dysregulated by insult or it tolerates such insult till certain limits.
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Figure 2. main factors and signaling involved in hepatocarcinogenesis.
Tissue associated biomarkers of hepatocellular carcinoma 
39Biomarkers in CanCer 2016:8(s1)
or device prognostic measures to prevent HCC in the past 
couple of decades.25–28 Here, we focus on some of the poten-
tial tissue biomarkers of HCC that function as appropriate 
targets for early diagnosis and development of antimetastatic 
vaccines/drugs.
Glypican-3. Glypican-3 (GPC3), a potent tissue bio-
marker of HCC, links to the cell membrane by a glycosylphos-
phatidylinositol anchor. It is a heparan sulfate proteoglycan 
that is involved in regulating the cell growth. Besides, GPC3 
can remove growth factors, such as hepatocyte growth factor 
(HGF) and vascular endothelial growth factor (VEGF), from 
the cell surface and inhibit the growth of HCC.29,30 GPC3 
is particularly expressed in HCC, but it is not produced by 
normal or cirrhotic hepatic cells.29,31 Genetic studies in many 
mammals exhibited that glypicans can regulate the signaling 
of Wnt, hedgehog, and FGF.32–35
The glypicans interact with Wnts and their 
signaling receptors, the frizzleds.36 The GPC3 stimulates 
Wnt  signaling activity by stabilizing the interaction with 
of Wnt with frizzled, resulting in the proliferation of the 
HCC cells. The GPC3-induced stimulatory activity requires 
the attachment of GPC3 to the cell membrane.36 In a study 
by Zittermann et al,30 it was demonstrated that a mutant 
GPC3 could not attach to the cell membrane (sGP3) and 
is secreted extracellularly (in the serum) and, thus, could 
remove the autocrine/paracrine Wnt from the cell surface of 
the HCC. The removal of Wnt could inhibit the prolifera-
tion of HCC and block the activity of FGF, VEGF, epider-
mal growth factor, and HGF.37–39 Hence, sGPC3 (mutant 
GPC3) is a potent tissue biomarker that can be targeted for 
HCC management.
Heat shock protein 70. Heat shock protein 70 (HSP70) is 
an essential molecular chaperon upregulated in response to heat, 
stress, or cell survival protection, tightly controlled by heat shock 
factor-1 (HSF-1). Studies have demonstrated that HSF-1 and 
HSP70 are involved in HCC tumor invasion and metastasis.40,41 
It has been demonstrated that 14-3-3σ protein induces HSP70 
via a β-catenin/HSF-1-dependent pathway, which in its down-
stream modulates HCC.42 Hence, 14-3-3σ–HSF-1 or HSF-1/
HSP70 complex is another important tissue biomarker to be 
targeted for developing a prognostic tool for HCC.
Tumor-associated glycoprotein 72. Tumor-associated 
glycoprotein 72 (TAG-72) is a cell membrane mucin-like glyco-
protein complex, overexpressed in many of human adenocarci-
nomas but not in normal tissues.43–45 In a study by Zhang et al,46 
it was demonstrated that TAG-72 is a new tissue biomarker in 
HCC that indicates the poor survival of patients (Fig. 5).
Figure 3. mechanism of action of sGPC3. (A) Wild-type GPC3 bound to the cell membrane facilitates/stabilizes the interaction of Wnt and other growth 
factors (bFGF and HGF) with their signaling receptors. (B) sGPC3 sequesters growth factors and inhibits their interaction with signaling receptors.  
© 2009 UiCC, reused with permission from Zittermann si, Capurro mi, shi W, Filmus J. soluble glypican 3 inhibits the growth of hepatocellular  
carcinoma in vitro and in vivo. Int J Cancer. 2010;126:1291–1301.
Figure 4. 14-3-3–HSF-1/HSP70 cell signaling in HCC cells. Modified 
from Wu YJ, Jan YJ, ko Bs, Liang sm, Liou JY. involvement of 14-3-3 
proteins in regulating tumor progression of hepatocellular carcinoma. 
Cancers. 2015;7(2):1022–1036, under the Creative Commons 
attribution License.
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Table 1. Biomarkers, their origin, and the significance.
NAME CATEGORY DESCRIPTION REFERENCE
alpha Fetoprotein (aFP) serum glycoprotein antigen aFP .500 ng/mL are indica-
tive of HCC, early diagnosis and 
monitoring
61, 226, 227
Glypican 3 (GPC3) Tissue biomarker-membrane bound 
heparin sulfate proteoglycan
GPC3 mrna and protein 
significantly upregulated in HCC 
specifically, early diagnosis
29, 228
Des-Gamma Carboxyl Prothrombin (DCP) Cellular enzyme-secreted by the 
cancerous hepatocyte (serum 
biomarker)
DCP .0.1 aU/mL (100 ng/mL) are 
highly suggestive of HCC, early 
diagnoses, metastasis
229
Gamma Glutamyl Transferase (GGT) serum biomarker GGTII isoform significantly 
upregulated in HCC
230
alpha-1-Fucosidase (aFU) Lysosomal enzyme, serum biomarker more than 2-fold increase in HCC 
patients compared to normal, 
liver cirrhosis or chronic hepatitis 
patients, early diagnosis
86
Dkk-1 serum/secreted protein biomarker enhances HCC progression by 
accumulation of beta-catenin  
by Wnt signaling, early  
HCC biomarker
76, 231
Human carbonyl reductase-2 secreted by Liver and kidney, serum 
biomarker
Detoxicating enzyme, level falls in 
HCC, prognosis
80
Golgi Phosphoprotein-2 (GoLPH2)/Golgi 
protein 73 (GP73)
serum biomarker Increased significantly, higher 
sensitivity than aFP, tumor 
aggressiveness
232
Transforming Growth factor beta 
(TGF-beta)
serum biomarker Tumor invasiveness, mrna 
overexpressed in HCC tissue
233–235
epidermal Growth Factor receptor Family 
(eGFr)
Cellular (transmembrane) biomarker early recurrence and reduced 
disease-free survival fol-
lowing resection of hepatocellular 
carcinoma
236
Hepatocyte Growth Factor (HGF) serum biomarker (cytokine) Prognosis, invasiveness and 
metastasis
237
Fibroblast Growth factor (FGF) Heparin binding polypeptide FGF level .10.8 pg/mL predicts 
HCC and reduced disease free 
survival
238
molecular markers
•	 aFP mrna
•	 GGT mrna, type B
•	 (insulin-like Growth factor) iGF-ii mrna
•	 albumin mrna
•	 mirna (micro rnas)
serum biomarker HCC tissue
serum biomarker
serum biomarker
nucleotide biomarker
increased postsurgical circula-
tion depicts more chances of 
recurrence, extrahepatic metas-
tasis, monitoring of postoperative 
recurrence, tumor spread and 
survival
184, 
239–245
Pathological biomarkers
•	 Heat shock Protein (HsP70)
•	 Glutamine synthase
•	 ki-67
•	 survivin
•	 e-Cadherin
•	 Vascular endothelial Growth Factor 
(VeGF)
Tissue biomarker increased transformed cell 
proliferation, survival, cell-to-cell 
adhesion, neoangiogenesis
246
Hepatocyte Paraffin 1 (HepPar1) Tissue biomarker Decreased expression in HCC 
cells
247
squamous Cell Carcinoma antigen 
(sCCa)-igm immunocomplex
serum biomarker Significant enhancement during 
progression to HCC
248,249
Tumor associated Glycoprotein 72 
(TaG-72)
Tissue biomarker Upregulation indicates tumor 
progression and metastasis, 
associated with poor survival 
46
Zinc-α2-glycoprotein (ZaG) serum biomarker (soluble glycoprotein) overexpressed in HCC 250
DLk-1 (Delta like protein-1) embryonic, kidney and neural tissue Significantly elevated in HCC 251
Villin 1 (Vil1) HCC tumor tissue Upregulated Vil1 indicates 
transformation, vascular invasion 
and cancer progression
252
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used for the diagnosis of HCC by clinicians; however, the 
specificity and reliability of AFP biomarker is questioned, and 
it is of less value in the early stages of HCC when the tumor 
size is ,3 cm.62
AFP-L3. It is a different form of AFP that differs in 
binding affinity with a lectin Lens culinaris agglutinin. This form 
of AFP-L is used as an early biomarker of HCC when the size 
of tumor is ,2 cm. As the size of tumor increases, the sensi-
tivity of this marker is increased.63 AFP-L is connected with 
Ki-67; as a marker of increased nuclear expression of Ki-67, there 
is a decrease in the expression of β-catenin, which is associated 
with distant metastasis.64 In case of the AFP-negative HCC, 
β-catenin positivity is more common.65
Glycoprotein 73. Glycoprotein 73 (GP73) is a type II 
Golgi-localized phosphoprotein, encoded by Golgi trans-
membrane type II (GOLPH2) gene located on chromosome 
9q21. It is expressed in epithelial cells in several human tissues 
and was first identified by serum glycoproteomics.66 GP73 
is highly expressed in the tumor part of the liver; however, 
its expression is comparatively very less in normal part of the 
same liver.67,68 Similar observations were noted in woodchuck 
animal model of HCC.67 Interestingly, it can differentiate 
patients developing cirrhosis with that of high-grade HCC 
and is also an early biomarker of HCC. During insult to the 
liver, ie, acute hepatitis and autoimmune hepatitis, GP73 is 
highly expressed. Viral infections are also found to increase 
the GP73 secretion.69 Oncostatin M, produced in the adipose 
tissues and a proinflammatory cytokine IL-6, increases the 
mRNA levels of GP73 as detected in HepG2 cell lines.70 In 
addition to HCC, it has been found in other cancers, such as 
lung adenocarcinoma, testicular seminomas, renal cell carci-
noma, and prostate cancer; however, in prostate cancer, it is 
detected only in urine and not in serum and, therefore, not a 
specific liver cancer biomarker.71 As given in Figure 6A, there 
are two major isoforms of GP73: one is complete and another 
is incomplete. In the incomplete form, first 10 amino acids at 
the N-terminal region are lacking and may have functional 
implications.
APO-J. APO-J is a glycoprotein with seven glycosylated 
sites and is also known as clusterin.72 It is more sensitive and 
specific than AFP.73 APO-J is significantly decreased in HCC 
patients compared to healthy controls and can be used as an 
independent marker of HCC.72 One of the recent studies also 
showed that it can be used as a prognostic marker and can also 
monitor HCC progression and metastasis.74,75
DKK-1 Dickkopf-p1. DKK biomarker is of high 
importance in cases where AFP biomarker misses HCC 
diagnosis. Importantly, it can diagnose HCC in very early 
stages of cancer.76,77 One of the studies by Zhu et al reported 
that DKK-1 can be used as a biomarker for HCC patients 
undergoing liver transplantation (LT) and can predict the 
prognosis of such patients.78 Studies on this biomarker are 
ongoing, and more robust studies are required to consider it 
as a biomarker.
Figure 5. TaG-72 as a potent prognostic marker in various cancers: Curves 
showing an estimate of overall survivability of cancer patients with absence 
of TaG-72 expression and presence of TaG-72 expression in cancer tissue 
after days of treatment.
Ki-67 antigen. Ki-67 is a nuclear protein associated with 
cellular proliferation.47 The Ki-67 levels were expressed sig-
nificantly correlating with higher increases from grades I to 
IV HCC tumors. This proliferative marker, with increased 
expression, indicated increased severity or spread of HCC 
(ranging from a mean+/- SD of 4.1+/-4.01 in tumor grade I 
to 29+/-15.01 in grade IV tumors).48
Hepatocyte paraffin 1. Hepatocyte paraffin 1 (HepPar1) 
is a monoclonal antibody prepared from a failed liver allograft,49 
which recognizes an epitope that is a component of hepatic 
mitochondria and not found in other normal tissues.49,50 Hep-
Par1 is often used as a marker to distinguish between HCC 
and secondary or metastatic hepatic neoplasms.51,52 A strong 
HepPar1 expression was detected in majority of the HCC 
tumors (35 out of 48 HCCs),53 whereas it was also expressed 
in nonhepatic tumors, such as lung, gallbladder, stomach, 
pancreas, colon, and malignant melanoma, but to a much 
lesser extent.54–58
HERC5. Homologous to the E6-AP carboxyl termi-
nus (HECT) domain and RCC-1-like domain-contain-
ing protein 5 is E3 ligase that conjugates with ISG15 to 
regulate several proteins. One of the main mechanisms of 
action of this molecule is by induction of CCL20, which 
in turn increases  T   regulatory infiltration, and it is one 
of the important prognostic biomarkers for tumor recur-
rence in HCC patients as well as survival in liver trans-
plant patients.59 It is also an important biomarker in the 
prognosis of lung cancer, and hypermethylation of promoter 
of HERC5 was associated with poor survival of stage 1 
adenocarcinoma.59,60
Serum Biomarkers of HCC
Alpha fetoprotein. Alpha fetoprotein (AFP) is produced 
by embryonic liver cells during pregnancy. It is in abundance 
during gestational stages, but its production is minimal after 
birth.61 AFP is one of the most common serum biomarkers 
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(PIVKA-II). During insult to the liver cells, when normal 
cells convert to fibroid cells or epithelial-to-mesenchymal 
transition, hypoxic shock leads to the induction of DES.84
a-1-Fucosidase. α-1-Fucosidase is a lysosomal enzyme 
that hydrolyzes fucose glucosidic bonds of glycolipids and 
glycoprotein. Its expression increases with liver insult simi-
lar to chronic hepatitis, cirrhosis, and HCC patients.85 It is 
one of the early HCC biomarkers and has a cut-off value of 
870 nm/mL/h. Interestingly, it is raised preceding six months 
of development of HCC, and its value is over 700 nm/mL/h 
in 85% of HCC patients.86
Hepatocyte growth factor. HGF is a cytokine pro-
duced by nonparenchymal Ito cells in the liver.87 It stimulates 
the expression of immediate early genes in primary cultures 
of hepatocytes.88 In hepatic regeneration, chronic hepatitis, 
cirrhosis, and HCC, HGF levels increase, and a level of 1.0 ng/mL 
indicates poor survival.89 It acts as a prognostic biomarker and 
can predict the early tumor recurrence and metastasis.90
Nerve growth factor. Nerve growth factor (NGF) 
is a member of neurotrophin family and is important for 
differentiation, survival, and preservation of peripheral and 
???????????? ??????????????????????? ?????????????????????????????????????????????????? ??? ????????????????? ???????????? ????????? ?????????????????? ????????????? ?????????????????????????????????????
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Figure 6. (A) alignment of the amino acid sequence of the two isoforms of GP73 taken from Uniprot protein iD-Q8nBJ4-1 and Uniprot protein 
iD-Q8nBJ4-2. Three blue box represents the glycosylation sites in two isoforms. Compared to isoform-1, isoform-2 is 10 amino acid shorter in n-terminal 
region. (B) increased expression of GP73 in cirrhosis and HCC compared to the healthy controls. increased expression of GP73 in patients infected 
with HBV-associated HCC and cirrhosis. Increased expression also correlates with the grading of the liver necroinflammation. Panel (B) is reused from 
Xu Z, Liu L, Pan X, et al. serum golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. Tarantino G, ed. Medicine. 
2015;94(12):e659, under the Creative Commons attribution License.
Human carbonyl reductase-2. It is expressed in human 
liver as well as kidneys. During oxidative stress, the released 
reactive oxygen species and alpha dicarbonyl are detoxified by 
this enzyme.79 The expression of human carbonyl reductase-2 
(HCR2) is significantly decreased in the tumor part of the liver 
compared to the normal cells.80 The decreased expression of car-
bonyl reductase-2 leads to cancer growth as it triggers the cell 
damage through reactive oxygen species and other carcinogens.
Midkine. Midkine is expressed at the time of early 
embryogenesis and is a heparin-binding growth factor. It 
is expressed during wound healing, tumorogenesis, and 
inflammation.81 Compared to AFP, which is significantly 
raised during advanced stages of HCC, midkine is margin-
ally raised and cannot be used as the biomarker in advanced 
stages of HCC. However, midkine expression markedly rises 
during early development of HCC.82
Des-γ-carboxy prothrombin. It is an important bio-
marker in large size HCC, and in cases where AFP misses 
HCC diagnosis, des-γ-carboxy prothrombin is able to detect 
HCC.83 It is an abnormal prothrombin protein of VEGF 
family expressed during vitamin K deficiency/antagonist-II 
Tissue associated biomarkers of hepatocellular carcinoma 
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central nervous systems.91 NGF levels are associated with 
tumor growth, invasion, and metastasis. There are two recep-
tors of NGF: high-affinity trkANGF and low-affinity p75NTR. 
Expression of NGF and trkANGF increases significantly during 
HCC. It can differentiate between cirrhosis that develops to 
HCC and cirrhosis that does not lead to HCC.92
Vascular endothelial growth factor. VEGF is a gly-
cosylated cytokine that acts as a mitogen and mediates 
vascular permeability, angiogenesis, vasculogenesis, and 
endothelial cell growth-reduced survival.93 Tumor charac-
teristic and environment promotes VEGF expression and 
initiates VEGF signaling and thus triggers downstream 
MAPK cascade (Ras/RAF/MEK/ERK) which is involved 
in angiogenesis, proliferation and metastasis and is shown in 
Figure 7. VEGF levels envisage HCC recurrence, and it is a 
substantial biomarker for the survival of HCC patients.94,95 
A phase III clinical study conducted on 602 HCC patients 
receiving sorafenib showed that VEGF was one of the mol-
ecules that predicted patients’ survival suggesting its role as 
a biomarker in the prognosis of HCC.96
Transforming growth factor-β. TGF-β plays an impor-
tant role in the control of cellular proliferation and differen-
tiation in HCC cells. Serum TGF-β levels are raised in HCC 
patients and is a long sought biomarker of HCC.97 One of the 
recent reports documented the role of the TGF-β-interacting 
factor as one of the prognostic biomarkers of HCC.98 More-
over, its partner mucin1 mediates TGF-β signaling by activat-
ing JNK/AP1 pathway and can also be used as a therapeutic 
target for the treatment of HCC.99
Epidermal growth factor. Epidermal growth factor 
receptor (EGFR) signaling is one of the important players 
in all the phases of hepatic injury from very early stages of 
inflammation to HCC development, including fibrogenesis 
and neoplastic transformation.100 One of the forms of EGFR, 
ErbB3, was detected in the serum of HCC patients during 
the early stages of HCC development and was associated 
with portal vein invasion and metasatsis.101 One of the recent 
studies reported that HBV HBx protein downregulates the 
EGFR expression by inducing miRNA-7 in HCC cells.102 In 
addition, it is an important player and has tumor promoting 
role in non-HCC cells via live resident macrophages.103 Using 
an in vivo model, a recent study determined the potential role 
of soluble EGFR in HCC metastasis.104
Wnt. Wnt-1 protein has been described as a prog-
nostic biomarker of HBV-related and HCV-related HCC 
after surgery.105 GPC3 molecule, which is described in the 
“Glypican-3” section, promotes the growth of HCC by stimu-
lating Wnt signaling.106
Angiopointin-1/2. Angiopointin-2 levels are raised in 
HCC and cirrhosis, and it has been documented by several 
Figure 7. Interaction between VEGF, VEGFR-2, and sVEGFR-2 via MAPK pathway. Modified from Ratnasari N, Yano Y. Do soluble vascular endothelial 
growth factor and its receptors predict the progression of chronic hepatitis to hepatocellular carcinoma? Hepatitis. 2015;1(1):4, under the Creative 
Commons attribution License.
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studies that elevated levels of Ang2 could be used as a marker 
of advanced pathological invasiveness and overall survival of 
HCC patients.96,107,108 It is also shown that Ang2 contributes 
to multiple organ failure and sepsis.109
NOTCH. Activation of NOTCH plays a prominent role 
in HBV-mediated HCC by proliferating hepatic cells and further 
supporting the growth of HCC, and this is also proved in in vivo 
mouse models.110,111 NOTCH1 is one of the possible therapeu-
tic targets for the treatment of HBx-associated HCC.112 Recent 
studies showed that NOTCH1 and NOTCH4 are important 
biomarkers revealing the poor prognosis of HCC.113,114
Oncostatin M. OSM is a member of cytokine family, 
which is very early secreted from the hematopoietic cells, and 
induces the differentiation of hepatocytes by regulating HNF4 
alpha.115 It regulates cytokine production, such as IL-6, GM-
CSF, and G-CSF. It is also shown to be elevated in HCC and 
acts in synergy with IL-6.116
Alpha-1 antitrypsin. Alpha-1 antitrypsin is a member of 
the SERPINA1 family of proteins, which is controlled by IL-6, 
TNα, and IL-1.117,118 Increased levels of A1AT have been asso-
ciated with HCC. A recent study revealed changes in the status 
of A1AT glycosylation during HCC and also documented that 
the core fucosyalation of HCC is one of the main reasons behind 
such changes.119 Compared to cirrhosis, it is significantly elevated 
in HCC and could also be used as a differentiation marker.120
WFA+ M2BP. Kuno et al121 first reported an assay that 
uses Wisteria floribunda agglutinin-positive human mac2-
binding protein in assessing liver fibrosis. A recent study by 
Yamasaki et al122 showed high value of measuring WFA+ 
M2BP and highlighted that it can be used as an indepen-
dent risk factor biomarker for HCC development. Interest-
ingly, WFA+ M2BP can predict HCC in HCV patients who 
respond well to the treatment and achieve the sustained viro-
logical response.123
Lymphotoxin beta receptor. Lymphotoxin beta recep-
tor is a cytokine and a member of tumor necrosis factor 
family, which is well known for controlling the development 
of lymphoid organs.124 In HCC as well as in cholangiocar-
cinoma cells, lymphotoxin beta receptor is vastly expressed 
and sustains the oncogene activity.125 It correlates with the 
upregulated Akt/NOTCH1 signaling and is a marker of poor 
survival in cholangiocarcinoma patients.126
Long Noncoding RNA as Biomarkers of HCC
MALAT1. Long noncoding RNA (lncRNA) is an 
RNA molecule with a length of 200  bp to 100  kbp and 
lacks protein-coding capacity. Metastasis-associated lung 
adenocarcinoma transcript 1 is the lncRNA of .8  kbp 
transcribed from chromosome 11q13. Recently, Lai et al127 
reported that an overexpressed MALAT1 transcript could 
predict HCC recurrence after LT and importantly in those 
patients whose survival rate was also reduced. There are five 
SP-binding motifs upstream of the MALAT1, which lead to 
its overexpression,128 In addition, an in vitro study suggested 
an interaction of hn-RNP-C with MALAT1 regulating cell 
cycle as recently studied in HepG2 cells.129
HOTAIR. Hox antisense intergenic RNA plays 
a role in chromatin dynamics, cell differentiation, and can-
cer metastasis, which is encoded by HOXC gene cluster.130 
Once transcribed, it acts in trans to control the HOXD genes 
by recruiting the polycomb repressive complex 2 and silenc-
ing the transcriptional machinery.131 Patients with elevated 
expression of HOTAIR shows poor prognosis compared to 
those with reduced HOTAIR expression. Yang et al132 docu-
mented that HOTAIR can act as an independent prognos-
tic biomarker in predicting the HCC recurrence in patients 
undergoing LT.
H19. Oncofetal H19 mRNA is abundantly expressed in 
the fetus.133 It is paternally imprinted, which resides at chro-
mosome 11p15.5 and is significantly expressed during tumor-
ogenesis. Compared to AFP, the expression of H19 mRNA 
is much higher in HCC cases.134 It also inhibits metastasis by 
stimulating miRNA-200 and inducing histone acetylation.135
Highly upregulated in liver cancer. Highly upregulated 
in liver cancer is a 500 nucleotide lncRNA, which is expressed 
from chromosome 6p24.3136 loci. Compared to normal liver 
tissue, it is highly expressed in adjacent tumor part of the 
liver.137 One of the main agents responsible for HCC is HBV 
infection, particularly HBx. A recent study by Du et al138 
documented an important role of highly upregulated in liver 
cancer in HBx-mediated HCC and further implicated that it 
is possible due to the downregulation of p18.
Long interspersed nuclear element-1. Retrotransposons 
are the jumping genes, and long interspersed nuclear element-1 
(LINE-1) is one of the autonomously regulated retrotrans-
posons. A recent study by Tangkijvanich et al139 tested the 
hypomethylation status of LINE-1 in 85 patients and con-
cluded that advanced disease and tumor size are associated 
with levels of LINE-1 hypomethylation. Another report by 
Piao et al highlighted the role of LINE-1 hypomethylation 
in early childhood tumorogensis.140 Gao et al141 also precisely 
documented that hypomethylation at two of the sites, CpG 7 
and 18, is associated with poor prognosis in HCC.
Micro-RNA biomarkers of HCC.
Micro-RNA and its role as biomarkers. A micro-RNA 
(miRNA) is a small noncoding RNA molecule that mainly 
functions in RNA silencing.142 Transcription of miRNA ini-
tiates from intronic region of a host gene leading to long pri-
miRNA transcript. This is further processed to pre-miRNA, 
Pre-miRNA then transport to cytoplasm by Exportin, where 
it goes through further modification by Dicer developing into 
complete miRNA molecule as given in Figure 8. miRNAs 
exhibit their silencing activities by base pairing with comple-
mentary sequences within mRNA molecules,143 by cleavage 
of the mRNA, chopping off its poly(A) tail, or less efficient 
translation of the mRNA into protein by ribosomes.144 The 
human genome encodes for over 1000 miRNAs,145 most of 
which are abundant in many mammalian cell types.146
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Figure 8. Biogenesis of miRNA. Modified from Anwar SL, Lehmann 
U. micrornas: emerging novel clinical biomarkers for hepatocellular 
carcinomas. Journal of Clinical Medicine. 2015;4(8):1631–1650, under 
the Creative Commons attribution License.
Several studies indicate that miRNAs are involved in a 
variety of physiological processes, including cell prolifera-
tion, differentiation, metabolism, and apoptosis. As given in 
Figure  9, miRNAs regulate important cellular angiogenesis, 
apoptosis and metastasis pathways. The miRNA was recog-
nized as a distinct class of biological regulators during early 
2000s.147,148 Ongoing research has identified different miR-
NAs expressed in different cells and tissues.146,149 miRNAs are 
detectable and stable in clinical samples, such as blood, serum, 
plasma, urine, and feces. Besides, the abnormal expression of 
miRNAs has been observed under different disease conditions, 
especially cancers, establishing miRNA as an important bio-
marker. Hence, new miRNA-based therapies are now under 
investigation.150–153
Role of miRNA biomarkers in HCC. miRNA dysregulation 
has been known to be associated with many cancers, the first 
studied being lymphocytic leukemia,154 and hence sometimes 
referred to as oncomirs. miRNA levels are also used as 
prognostic for cancers, as low miR-324 levels could serve as 
indicator of poor survival in non-small-cell lung carcinoma 
samples.155 High miR-185 or low miR-133b may correlate with 
metastasis and poor survival in colorectal cancer.156 miR-10b 
is implicated in the metastasis of breast cancer cells157 and the 
development of gastric cancer and pancreatic cancer.158,159
A number of studies have demonstrated extensive miRNA 
dysregulation in various stages of HCC.160 Furthermore, 
unique patterns of miRNA expression could be utilized as 
potential biomarkers for diagnosis, prognosis, staging, and 
prediction of therapeutic responses in HCC.161–163 Expression 
of particular miRNAs tends to change gradually during the 
progression of HCC, and many tumor suppressor genes are 
demonstrated as the targets of the HCC oncomirs (eg, PTEN 
for miR-21, miR-221, and miR-222). Specific signaling path-
ways, such as Wnt/β-catenin, RAS, TGF-β, and JAK/STAT, 
are established targets for miRNA dysregulation in HCC.163
A comprehensive demonstration of the role of miRNA 
dysregulation and differential miRNA expression in HCC has 
been done.164,165 The advantage of miRNAs is that they are 
stable in frozen samples, formalin fixed paraffin embedded tis-
sues, and body fluids, including plasma/serum, urine, and saliva. 
This property of miRNA makes them an excellent tool for early 
cancer diagnosis.
Primary tissue specimens. Basal miRNA expression has 
been studied using deep sequencing in primary HCC speci-
mens as well as in the healthy liver.165,166 The most abundant 
miRNA expressed in healthy liver is miR-122, which is com-
monly downregulated in HCC. miR-199a/b is also downreg-
ulated in HCC and associated with poor survival.166
Serum. Serum levels of miR-122 are significantly upreg-
ulated in HCC patients compared to healthy individuals, 
and the levels are decreased after therapy.167 A case study 
reported by Li et al168 involving 500 serum samples from 
HCC patients showed that a combination of three miRNAs’ 
profile change, such as miR-25, miR-375, and let-7f, could 
distinguish between HCC and healthy controls. Serum levels 
of miR-16, miR-195, and miR-199a, alone or in combination, 
could distinguish between HCC and chronic hepatitis.169 
Overexpression of miR-15b, miR-21, miR-130b, and miR-183 
is demonstrated in 96 tumors, which indicate that these cir-
culating miRNAs are derived from tumor cells.168 Lin et al170 
reported very recently that the cluster of seven miRNAs 
(miR-29a, miR-29c, miR-133a, miR-143, miR-145, miR-
192, and miR-505) can detect the HCC with better sensitiv-
ity and similar specificity than AFP. Another recent study 
demonstrated that low miR-150 level in HBV-related HCC 
patients was associated with a significantly decreased survival 
(P , 0.0001).161
Zhou et al171 reported that a particular miRNA panel 
was able to specifically distinguish HCC from healthy indi-
viduals and HBV and cirrhosis patients, using plasma samples 
from 934 HBV-associated HCC patients. For example, miR-
106 could distinguish between HCC from healthy individuals 
and chronic hepatitis patients;172 while four miRNA panels 
(miT-20a-5p, miR-320a, miR-324-3p, and miR-375) have 
a high sensitivity and specificity to differentiate HCC from 
benign liver lesions.173 These findings clearly demonstrate that 
circulating miRNAs could be a potential diagnostic marker 
in HCC. As given in Figure 10, distinctive miRNAs are 
up-/down-regulated in hepatitis, fibrosis, steatosis and HCC, 
however miRNA-21, miRNA-122 and miRNA-223 are 
involved in Hepatitis as well as HCC.
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Figure 9. mature mirnas silenced by aberrant Dna methylation and their affected target genes and pathways that are important in the development and 
progression of HCC.
Abbreviations: Pi3k, phosphatidylinositol-3-kinase; maPk, mitogen-activated protein kinase; eGF, epidermal growth factor; PDGF, platelet-derived 
growth factor; HGF, hepatocyte growth factor; mTor, mammalian target of rapamycin; VeGF, vascular endothelial growth factor; mmP, matrix 
metalloproteinase; aPC, activated protein C; CTnnB1, β-catenin.
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Figure 10. Summary of miRNAs and their targets associated with HCC, liver fibrosis, NAFLD, and hepatitis (HBV or HCV infection). miRNAs that are 
upregulated are indicated by red text, and mirnas that are downregulated are indicated by green text.
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miRNA as a prognostic tool in HCC. Other than their util-
ity as a diagnostic biomarker, miRNAs are also important as 
prognostic tool, able to determine the tumor size, nodal, and 
metastasis stage of HCC, invasion, recurrence, and overall 
survival. miR-25 has been demonstrated to have a signifi-
cant role in tumor size, nodal, and metastasis as reported by 
Su et al;174 upregulation of miR-183175 and miR-17-5p176 in 
primary HCC samples after surgery has been associated with 
large tumors and higher risk of metastasis. High miR-221 
expression, along with downregulation of miR-100 and 
miR-22, is demonstrated in primary HCC tissues with dis-
tant metastasis.177–179 miR-222 level is important to determine 
the advancement of the tumor.180 An overall miRNA profiling 
study demonstrated that upregulation of miR-25, miR-372, 
miR-155, and miR-182174,181–183 strongly correlates with 
shorter survival time, whereas downregulation of miR-29a-5p, 
miR-100, miR-29, miR-101, and miR-148a in HCC tissues 
depicts the cure of the HCC and an increased survival.177,184–186
miRNA as a therapeutic target. Currently, active research 
is going on to utilize these potential diagnostic and prognostic 
biomarkers as potential therapeutic targets to manage HCC. 
For therapy, antagonists are being developed against oncogenic 
miRNAs or oncomirs, referred to as antagomirs (locked 
nucleic acids). A very interesting example is of miravirsen 
(anti-miR-122) to treat chronic HCV infection, which is cur-
rently on phase III clinical trials.187 The success of the miRNA-
based therapy would definitely lead to the better effectiveness 
of the current interferon therapy by the downregulation of the 
cell signaling pathway that generally renders the cells’ inter-
feron resistant. It is reported that sorafenib, the drug used to 
treat HCC patients, regulates miRNA expression. Fourteen 
miRNAs are upregulated by sorafenib treatment. miR-122 
is an important liver-specific miRNA that maintains liver 
homeostasis, so the delivery of miR-122 in HCV-infected 
patients is currently on clinical  trials.188 miR-122, which is 
generally downregulated in HCC patients, is restored by 
sorafenib.189 Restoration of miR-122 by sorafenib also leads 
to an increased sensitivity of the tumors to other drugs, such 
as doxorubicin190 adriamycin, and vincristine.191 miR-26b has 
been shown to affect NF-κB signaling molecules to mediate 
chemosensitivity.192 Certain miRNAs when downregulated 
or upregulated induce drug resistance, hence they are targeted 
to develop their specific antagomirs to induce drug sensitivity 
for HCC treatment.
miRNA profiling and expression studies have tremendous 
potential for the development of new biomarkers, diagnostic 
and prognostic markers, as well as therapeutic molecules for 
the management of HCC. Hence, miRNAs are definitely the 
anticancer medicine for the future.
Tables 2A–C summarize the names and the roles of miR-
NAs as diagnostic, prognostic, and therapeutic markers, respec-
tively, in HCC.193
Exosomal miRNA as a biomarker of HCC. One of the recent 
studies by Sohn et al194 isolated exosomes from the serum of 
Table 2. This table summarizes the list of miRNA from different sources, being upregulated or downregulated during HCC, and their roles in 
HCC progression. A. Daignostic markers. B. Prognostic markers C. Therapeutic markers.
microRNA REGULATION SOURCE INFORMATION
A. Diagnostic biomarkers
mir-106 Up Plasma Differentiate HCC from healthy control and chronic disease
mir-122 Up serum Differentiate HCC from healthy control
mir-15b, mir-130b Up serum Differentiate HCC from healthy control
mir-16, mir-199a Down serum Differentiate HCC from healthy control and Chronic hepatitis
mir-183 Up Tissue Differentiate benign and malignant liver tumor
mir-15b, mir-130b Up serum Differentiate HCC and healthy patients and reduce after 
surgery
mir-18a Up serum Differentiate HCC from healthy control
mir-122, mir-192, mir-21, mir-223, 
mir-26a, mir-27a, mir801-
signature Plasma Differentiate HCC from healthy control
mir-21 Up serum, 
Plasma
Differentiate HCC from cirrhosis and healthy controls
mir-375 Up serum Differentiate HBV- and HCV-related HCC from healthy 
controls
mir-483 Up Plasma Differentiate HCC from healthy control
mir-618/mir-650 Up Urine Differentiate HCC and control
mir-885 Up serum Differentiate HCC, cirrhosis and chronic liver patients from 
healthy controls
mir-92a Down Plasma Differentiate HCC from healthy control
(Continued)
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Table 2. (Continued)
microRNA REGULATION SOURCE INFORMATION
mir-25, mir-375, let-7f Up serum Differentiate HCC from healthy control
mir-20a-5p, mir-320a, mir-324-3p, mir-375 Up Plasma Differentiate HCC from non-cancerous lesions
mir-29a, mir-29c, mir-133a, mir-143, 
mir-145, mir-192, mir-505
signature serum Detect early stage HCC and aFP-negative HCC
B. Prognostic markers
mir-10b Up Tissue Poor prognosis
mir-122 Down Tissue Poor prognosis
mir-124 Down Tissue Poor prognosis and aggressive type
mir-135a Up Tissue shorter overall survival and disease free survival
mir-139 Down Tissue metastasis and poor prognosis
mir-155 Up Tissue Poor prognosis, recurrence, micro-vascular invasion
mir-182 Up Tissue intrahepatic metastasis and poor prognosis
mir-199b-5p Down Tissue shorter overall survival
mir-203 Up Tissue Better prognosis, longer survival
mir-21, mir-221 Up Tissue Tumor stage and poor prognosis
mir-22 Down Tissue Poor survival
mir-221 Up Tissue Poor survival
mir-29 Down Tissue shorter disease free survival
mir-29a-5p Up Tissue recurrence in early stage of HCC
mir-99a Down Tissue shorter survival
Let-7g Down Tissue Poor survival
DLk1-Dio3 mirna cluster Up Tissue Poor prognosis
C19mC microrna cluster Up Tissue Poor clinico-pathological features, recurrence and shorter 
overall survival
mir-155, mir-15a, mir-432,
mir-486-3p, mir-15b, mir-30b
Up Tissue recurrence-free survival
mir-19a, mir-886, mir-43,
mir-486-3p, mir-15b, mir-30b
signature Tissue overall survival and recurrent free survival 
67 mirna signature signature Tissue Differentiate recurrence after liver transplantation
mir signatures in tumor and non-tumor 
tissues
signature Tissue Differentiate early and late recurrence
mir-326, mir-3677, mir-511-1,
mir-511-2, mir-9-1, mir-9-2
signature Tissue negatively associated with overall survival
C. Therapeutic markers
mir-122 Down Cells, tissue Decreased sensitivity to doxorubicin
mir-122 Down Cells, tissue Decreased sensitivity to adriamycin, vincristin
mir-122 Down Cells, tissue suppressed sensitivity to sorafenib
mir-146a Up Cells suppressed sensitivity to interferon-α
mir-193a-3p Down Cells, tissue resistance to 5-FU
mir-193b Up Cells, tissue sensitivity to cisplatin
mir-199a-3p Down Cells, tissue increased sensitivity to doxorubicin
mir-1247a Down Cells resistance to sorafenib
mir-21 Up Cells, tissue resistance to interferon-α/5-FU in HCC cells
mir-34a Down Cells, tissue resistance to sorafenib
13 microrna signature signature Cells, tissue multidrug resistance
Note: Taken from ref. 193.
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chronic hepatitis B (CHB), cirrhosis, and HCC patients and 
found elevated levels of miRNAs, such as miR-18a, miR-221, 
miR-222, and miR-224, in HCC patients compared to those 
with CHB or liver cirrhosis (Fig. 11), whereas serum levels of 
miR-101, miR-106b, miR-122, and miR-195 were lower in 
HCC patients compared to CHB patients.
Genetic Variants as Biomarkers
P53 A249S. AGG-to-AGT single-nucleotide transver-
sion leads to change of codon from arginine to serine at posi-
tion 249 of P53 gene and one of the important hotspot genetic 
variations in HCC.195 It is majorly detected in patients who are 
exposed to aflatoxin and HBV.196 Some recent investigations 
deciphered the mechanisms by which it leads to HCC devel-
opment: (1) inactivation of p16INK4 gene by overmethylation of 
this gene197 and (2) regulation of genes that play a main role in 
controlling the cell cycle switch from G to S phases.198
HBV core promoter mutations. HBV mutations in the 
basal core promoter region are important etiological risk factors 
for severe liver disease and HCC.199,200 BCP 1762 and 1764 muta-
tions identified as an independent risk factor of HCC.201,202 Using 
the plasma samples, two studies reported that these mutations 
have the high predictive power to reveal the predisposition to 
HCC and its development.203,204
HBV PreS1 mutations/truncations. One of the larg-
est studies, while recruiting 11,582 HBV-infected patients, 
reported that HBV preS mutants are associated with high risk 
of HCC.205 T53C, PreS2 initiation codon mutation, PreS1 
deletion, C7A, A2962G, C2964A, and C3116T were signifi-
cantly associated with HCC.201,206 One of the effects of few 
such mutations/deletions is that it also alters the overlapping 
polymerase gene reading frame; for example, rtA181T mutation 
in polymerase gene leads to stop codon mutation sW172 stop 
in the surface region and is associated with high risk of HCC 
development in patients’ refractory to the nucleoside therapy.207 
Due to PreS envelope protein mutations/deletions, high-level 
uneven expression of these proteins leads to endoplasmic retic-
ulum stress, causing genomic instability resulting in HCC.208
HBx region mutations and truncations. There are two 
main mechanisms by which HBV causes HCC, ie, direct and 
indirect. In direct mechanism, it integrates into the host liver cell 
genome and modulates several host genes in cis manner,209 and 
the indirect way is by trans activation of several genes by HBx 
protein.210 HBx protein in serum has been shown to be one of the 
markers of the liver cirrhosis and liver cancer in HBV-infected 
HCC.211 HBx induces AFP and promotes malignant transfor-
mation of hepatocytes by activating PI3K/mTOR signaling.212
Genetic Variations Identified by Next-generation 
Sequencing
Accumulation of genetic alterations is one of the most 
important mechanisms of causing HCC. Next-generation 
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Figure 11. The distribution of upregulated exosomal mirnas (mir-18a, mir-221, mir-222, and mir-224) in CHB patients, LC, and HCC. reprinted by 
permission from macmillan Publishers Ltd: experimental & molecular medicine, sohn W, kim J, kang sH. serum exosomal micrornas as novel biomarkers 
for hepatocellular carcinoma. Exp Mol Med. 2015;47:e184. Copyright 2015.
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sequencing (NGS) through whole genome, whole exome, 
and whole transcriptome approaches has lead to revolu-
tionary studies. A study by Ley et al213 reporting NGS, 
first described NGS as an unbiased method discovering 
cancer-initiating mutations. HBV integration into the host 
liver genome is considered as a direct way through which 
HBV causes HCC. Through NGS, three recent reports 
described HBV integration sites in the host liver genome. 
Using the whole genome sequencing, Jiang et al214 found 
255 HBV integration sites in only three patients. In the 
second study by Sung et al,215 399 integrations sites were 
identified 75 out of 81 HCC patients. In the third study, 
Toh et al used 48 patients and, using the deep sequencing-
mediated enrichment of HBV genomes, found that HBV 
integrates significantly in higher frequency in the regula-
tory regions of the host genes. It was reported that one of 
the important genes having recurrent HBV integration was 
TERT gene.216 A recent study also found important TERT 
promoter mutations in 60% of HCC patients, and other 
mutated genes identified were P53, CTNNB1, and ARID1 
genes.217 Although not by NGS,  but by clonal sequencing, 
our recent in-vitro study demonstrated that hepatitis B virus 
can integrate in the host genome immediately after infection, 
and the same was proved in in vivo study by infecting Wood-
chucks with Woodchuck hepatitis virus.218 Such HBV-host 
integration junctions possibly have the potential to act as very 
early molecular biomarkers of HBV related hepatocellular 
dysregulation. However, the question of whether they can act 
as a serum biomarker (fused virus-host protein secretion) will 
need further work and validations. Moreover, it will be inter-
esting to discover, if such virus-host fused, secreted, properly 
folded proteins indeed play a role in the development of hepa-
tocarcinoma and could be used as a prognostic biomarker or 
a therapeutic target. Using the whole-exome sequencing, a 
recent study for the first time identified recurrent alterations 
in four genes: AR1D1A, RPS6KA3, NFE2L2 and IRF2. 
In addition in  liver tumors G . T transversion were sig-
nificantly enriched in the non-transcribed DNA strand and 
highlighted  their role in HCC.219 This study demonstrated 
alterations in genes responsible for activating the PI3K/
Akt/mTOR pathway and an important mutation of mTOR 
at position S2215Y was reported.220
Summary
HCC, the neoplastic transformation of the hepatocytes, 
is one of the leading causes of cancer deaths around the 
world. People at risk of developing HCC include chronic 
liver disease patients with hepatitis B or C, obese or diabetic 
people, and heavy drinkers. HCC is developed as a conse-
quence of chronic liver cirrhosis, where there is a decrease 
in hepatocyte growth and proliferation, along with scar 
tissue formation, that provides the platform for neoplastic 
tumor growth. Current methods of HCC management and 
treatment are more tumor oriented (chemotherapy using 
drugs, radiotherapy, surgical methods, such as liver resec-
tion and transplantation, and ethanol injection in the tumor 
cells). However, these methods are more of a palliative 
approach to HCC, aiming to extend the life span of patients 
rather than devising a curative approach. Therefore, due to 
the lack of a proper curative treatment of HCC, it is very 
important to prevent the onset of HCC or make attempts to 
detect the disease at a very early stage. The purpose of this 
review is to present before the readers, scientists, and medi-
cal professionals a detailed report of the ongoing research 
aiming at the discovery of biological tools for the preven-
tion and prognosis of HCC. There are some biomolecules in 
the tissues and body fluids of humans whose levels change 
with the development of many abnormal conditions, various 
disease states, as well as carcinogenesis. These molecules, 
called biomarkers, are now regarded as important prog-
nostic tools for early diagnosis of HCC. Active research 
is being conducted both at the basic and clinical levels to 
accurately detect the molecular targets, for developing drugs 
and vaccines to cure or prevent HCC. Many classes of bio-
markers have been studied and detected in various stages 
of HCC (early and late), including peptides, glycoproteins, 
enzymes (soluble biomarkers), and mRNAs (nucleotide bio-
markers), and can be obtained from liver tissue and serum of 
HCC patients. These biomolecules have also shown strong 
promise as molecular targets for the development of anti-
metastatic vaccines or drugs. For example, some biomark-
ers, such as TAG-72, Golgi-localized phosphoprotein 73 
(GP73), enzymes, such as α-1-fucosidase, and HGF, are 
overexpressed in HCC tissues and indicate poor surviv-
ability in patients. There are other markers, such as HCR2 
enzyme, the glycoprotein APO-J/clusterin, that are reduced 
significantly during HCC progression and metastasis. From 
the start of the new millenium, miRNAs that are small 
non-coding RNA silencing molecules were recognized to 
be a new and distinct class of cancer biomarkers, especially 
in HCC. miRNAs that are effectively stable and easily 
extractable from tissues, plasma, serum, urine, and feces 
have shown great potential as prognostic tools and thera-
peutic targets in HCC.
This review has been documented to discuss the new 
research going on with an aim to harness the SOS signals of 
the human body, the biomarkers, to detect early and prevent 
HCC. The success of this research would bring a new era 
where not only HCC but also other cancers would no more be 
a death sentence.
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